J Korean Breast Cancer Soc.  2004 Dec;7(4):289-293. 10.4048/jkbcs.2004.7.4.289.

Feasibility of Concurrent Adjuvant Chemotherapy and Radiotherapy after Breast-conserving Surgery in Early Breast Cancer

Affiliations
  • 1Department of Surgery, Inje University Sanggye Paik Hospital, Seoul, South Korea. shwhan@unitel.co.kr
  • 2Department of Radiation Oncology, Inje University Sanggye Paik Hospital, Seoul, South Korea.
  • 3Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, South Korea.

Abstract

PURPOSE
The optimal sequence of chemotherapy (CT) and radiotherapy (RT) remains uncertain although both can reduce breast cancer recurrence after breast-conserving surgery (BCS). The current study was performed to evaluate whether concurrent RT with CT increases chemotherapy-associated toxicities. METHODS: Two hundred and thirty-eight patients with stage I and II breast cancers were prospectively allocated concurrent CT and RT (N=133) or sequential CT and RT (N= 105) after BCS. In the sequential group, the RT was started after completion of 3 cycles of CT with an additional 3 cycles of CT delivered after the RT. All patients underwent intravenous CMF chemotherapy composed of cyclophosphamide (500 mg/m2), methotrexate (50 mg/m2) and 5-FU (500 mg/ m2), every 3 weeks for 6 cycles following surgery. RESULTS: There were no significant differences between the two groups with regard to the grade 3 or 4 hematologic toxicities during chemotherapy or in abnormal liver enzyme elevation. Radiation related adverse effects, such as moist desquamation and pneumonitis symptom, were no different between the two groups. During the median 42 month follow-up period, range 16- to 60 months, 18 (13.5%) and 20 (19.1%) patients in the concurrent and sequential groups had systemic recurrences of breast cancer. The disease-free survival and local recurrence rates were no different between the two groups. CONCLUSION: Concurrent CT and RT were not associated with an increased toxicity and reasonable cosmetic results were achieved in this current study. The current study indicates that concurrent RT with CT after BCS is a feasible treatment modality, with the advantage of a shortening treatment time.

Keyword

Breast conserving surgery; Chemotherapy; Radiotherapy; Toxicity

MeSH Terms

Breast Neoplasms*
Breast*
Chemotherapy, Adjuvant*
Cyclophosphamide
Disease-Free Survival
Drug Therapy
Fluorouracil
Follow-Up Studies
Humans
Liver
Mastectomy, Segmental*
Methotrexate
Pneumonia
Prospective Studies
Radiotherapy*
Recurrence
Cyclophosphamide
Fluorouracil
Methotrexate

Cited by  2 articles

Toxicity of Concurrent Adjuvant CMF Chemotherapy and Radiotherapy in Patients with Early Breast Cancer
Cha-Kyong Yom, Hyun-Ah Kim, Byung-In Moon, Kuk-Jin Choe, Kum-Ja Choi, Hyun-Suk Suh, Hye-Young Choi
J Breast Cancer. 2007;10(2):147-152.    doi: 10.4048/jbc.2007.10.2.147.

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
Geumhee Gwak, Kyeongmee Park, Eunah Shin, Sehwan Han, Ji-Young Kim, Hongyong Kim, Young Duk Kim, Hong Ju Kim, Ki Whan Kim, Byung Noe Bae, Keun Ho Yang, Hyunjin Cho, Sung-Jin Park
J Breast Cancer. 2011;14(3):223-228.    doi: 10.4048/jbc.2011.14.3.223.

Full Text Links
  • JKBCS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr